Pubu M Abeyasinghe1, Jeffrey D Long2,3, Adeel Razi1,4,5, Dorian Pustina6, Jane S Paulsen7, Sarah J Tabrizi8, Govinda R Poudel9, Nellie Georgiou-Karistianis1. 1. School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia. 2. Department of Psychiatry, Carver Collage of Medicine, The University of Iowa, Iowa City, Iowa, USA. 3. Department of Biostatistics, College of Public Health, The University of Iowa, Iowa City, Iowa, USA. 4. Monash Biomedical Imaging, Monash University, Clayton, Victoria, Australia. 5. Wellcome Centre for Human Neuroimaging, UCL, London, United Kingdom. 6. CHDI Management/CHDI Foundation, Princeton, New Jersey, USA. 7. Department of Neurology, University of Wisconsin, Madison, Wisconsin, USA. 8. UCL Department of Neurodegenerative Disease and Huntington's Disease Centre, UCL Queen Square Institute of Neurology, Dementia Research Institute at UCL, London, United Kingdom. 9. Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Potential therapeutic targets and clinical trials for Huntington's disease have grown immensely in the last decade. However, to improve clinical trial outcomes, there is a need to better characterize profiles of signs and symptoms across different epochs of the disease to improve selection of participants. OBJECTIVE: The objective of the present study was to best distinguish longitudinal trajectories across different Huntington's disease progression groups. METHODS: Clinical and morphometric imaging data from 1082 participants across IMAGE-HD, TRACK-HD, and PREDICT-HD studies were combined, with longitudinal times ranging between 1 and 10 years. Participants were classified into 4 groups using CAG and age product. Using multivariate linear mixed modeling, 63 combinations of markers were tested for their sensitivity in differentiating CAG and age product groups. Next, multivariate linear mixed modeling was applied to define the best combination of markers to track progression across individual CAG and age product groups. RESULTS: Putamen and caudate volumes, individually and/or combined, were identified as the best variables to both differentiate CAG and age product groups and track progression within them. The model using only caudate volume best described advanced disease progression in the combined data set. Contrary to expectations, combining clinical markers and volumetric measures did not improve tracking longitudinal progression. CONCLUSIONS: Monitoring volumetric changes throughout a trial (alongside primary and secondary clinical end points) may provide a more comprehensive understanding of improvements in functional outcomes and help to improve the design of clinical trials. Alternatively, our results suggest that imaging deserves consideration as an end point in clinical trials because of the prospect of greater sensitivity.
BACKGROUND: Potential therapeutic targets and clinical trials for Huntington's disease have grown immensely in the last decade. However, to improve clinical trial outcomes, there is a need to better characterize profiles of signs and symptoms across different epochs of the disease to improve selection of participants. OBJECTIVE: The objective of the present study was to best distinguish longitudinal trajectories across different Huntington's disease progression groups. METHODS: Clinical and morphometric imaging data from 1082 participants across IMAGE-HD, TRACK-HD, and PREDICT-HD studies were combined, with longitudinal times ranging between 1 and 10 years. Participants were classified into 4 groups using CAG and age product. Using multivariate linear mixed modeling, 63 combinations of markers were tested for their sensitivity in differentiating CAG and age product groups. Next, multivariate linear mixed modeling was applied to define the best combination of markers to track progression across individual CAG and age product groups. RESULTS: Putamen and caudate volumes, individually and/or combined, were identified as the best variables to both differentiate CAG and age product groups and track progression within them. The model using only caudate volume best described advanced disease progression in the combined data set. Contrary to expectations, combining clinical markers and volumetric measures did not improve tracking longitudinal progression. CONCLUSIONS: Monitoring volumetric changes throughout a trial (alongside primary and secondary clinical end points) may provide a more comprehensive understanding of improvements in functional outcomes and help to improve the design of clinical trials. Alternatively, our results suggest that imaging deserves consideration as an end point in clinical trials because of the prospect of greater sensitivity.
Authors: Kevin M Biglan; Christopher A Ross; Douglas R Langbehn; Elizabeth H Aylward; Julie C Stout; Sarah Queller; Noelle E Carlozzi; Kevin Duff; Leigh J Beglinger; Jane S Paulsen Journal: Mov Disord Date: 2009-09-15 Impact factor: 10.338
Authors: Alissa L Nana; Eric H Kim; Doris C V Thu; Dorothy E Oorschot; Lynette J Tippett; Virginia M Hogg; Beth J Synek; Richard Roxburgh; Henry J Waldvogel; Richard L M Faull Journal: J Huntingtons Dis Date: 2014
Authors: Juan F Domínguez D; Govinda Poudel; Julie C Stout; Marcus Gray; Phyllis Chua; Beth Borowsky; Gary F Egan; Nellie Georgiou-Karistianis Journal: Cortex Date: 2017-04-15 Impact factor: 4.027
Authors: Simon F Eskildsen; Pierrick Coupé; Daniel García-Lorenzo; Vladimir Fonov; Jens C Pruessner; D Louis Collins Journal: Neuroimage Date: 2012-10-02 Impact factor: 6.556
Authors: Juan F Domínguez D; Julie C Stout; Govinda Poudel; Andrew Churchyard; Phyllis Chua; Gary F Egan; Nellie Georgiou-Karistianis Journal: Br J Psychiatry Date: 2015-12-17 Impact factor: 9.319
Authors: Stefan Klöppel; Sarah Gregory; Elisa Scheller; Lora Minkova; Adeel Razi; Alexandra Durr; Raymund A C Roos; Blair R Leavitt; Marina Papoutsi; G Bernhard Landwehrmeyer; Ralf Reilmann; Beth Borowsky; Hans Johnson; James A Mills; Gail Owen; Julie Stout; Rachael I Scahill; Jeffrey D Long; Geraint Rees; Sarah J Tabrizi Journal: EBioMedicine Date: 2015-08-04 Impact factor: 8.143
Authors: Jane S Paulsen; Jeffrey D Long; Hans J Johnson; Elizabeth H Aylward; Christopher A Ross; Janet K Williams; Martha A Nance; Cheryl J Erwin; Holly J Westervelt; Deborah L Harrington; H Jeremy Bockholt; Ying Zhang; Elizabeth A McCusker; Edmond M Chiu; Peter K Panegyres Journal: Front Aging Neurosci Date: 2014-04-22 Impact factor: 5.750